21 Ljungberg K, Kolmskog C, Wahren B, et al. DNA vaccination of ferrets with chimeric influenza A virus hemagglutinin (H3) genes. Vaccine,2002, 20: 2045–2052？？
[3]
22 Cherbonnel M, Rousset J V J. Strategies to improve protection against low-pathogenicity H7 avian influenza virus infection using DNAvaccines. Avian Dis, 2003, 47: 1181–1186？？
[4]
23 Qiu M, Fang F, Chen Y, et al. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- orneuraminidase- expressing DNA in BALB/c mice. Biochem Biophys Res Commun, 2006, 343: 1124–1131？？
[5]
24 Laddy D J, Yan J, Corbitt N, et al. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine, 2007, 25:2984–2989？？
26 Carroll S M, Paulson J C. Differential infection of receptor-modified host cells by receptor-specific influenza viruses. Virus Res, 1985, 3:165–179？？
[8]
27 Wang S X, Taaffe J, Parker C, et al. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require differentantigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol, 2006,80: 11628–11637？？
[9]
28 Zheng L, Wang F Y, Yang Z D, et al. A single immunization with HA DNA vaccine by electroporation induces early protection againstH5N1 avian influenza virus challenge in mice. BMC Infect Dis, 2009, 9: 17？？
[10]
29 Zhang L, Widera G, Rabussay D. Enhancement of the effectiveness of electroporation-augmented cutaneous DNA vaccination by aparticulate adjuvant. Bioelectrochemistry, 2004, 63: 369–373？？
[11]
30 De Groot A S, Ardito M, McClainea E M, et al. Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenzaA (H1N1) virus with epitopes in 2008~2009 conventional influenza vaccine. Vaccine, 2009, 27: 5740–5747？？
[12]
1 Fries L F, Dillon S B, Hildreth J E, et al. Safety and immunogenicity of a recombinant protein influenza A vaccine in adult humanvolunteers and protective efficacy against wild-type H1N1 virus challenge. J Infect Dis, 1993, 167: 593–601
[13]
2 Steitz J, Barlow P G, Hossain J, et al. A candidate H1N1 pandemic influenza vaccine elicits protective immunity in mice. PLoS One, 2010,5: e10492？？
[14]
3 Kong W P, Hood C, Yang Z Y, et al. Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. Proc NatlAcad Sci USA, 2006, 103: 15987–15991？？
[15]
4 Kodihalli S, Kobasa D L, Webster R G . Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines.Vaccine, 2000, 18: 2592–2599？？
[16]
5 Kodihalli S, Goto H, Kobasa D L, et al. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virusinfection in mice. J Virol, 1999, 73: 2094–2098
[17]
6 Ljungberg K, Wahren B, Almqvist J, et al. Effective construction of DNA vaccines against variable influenza genes by homologousrecombination. Virology, 2000, 268: 244–250？？
[18]
7 Ljungberg K, Kolmskog C, Wahren B, et al. DNA vaccination of ferrets with chimeric influenza A virus hemagglutinin (H3) genes. Vaccine,2002, 20: 2045–2052？？
[19]
8 Lee C W, Senne D A, Suarez D L. Development of hemagglutinin subtype-specific reference antisera by DNA vaccination of chickens.Avian Dis, 2003, 47: 1051–1056？？
[20]
9 Chen Z, Sahashi Y, Matsuo K, et al. Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza.Vaccine, 1998, 16: 1544–1549？？
[21]
10 Chen Z, Kadowaki S, Hagiwara Y, et al. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase.Vaccine, 2000, 18: 3214–3222？？
[22]
11 Kadowaki S, Chen Z, Asanuma H, et al. Protection against influenza virus infection in mice immunized by administration ofhemagglutinin-expressing DNAs with electroporation. Vaccine, 2000, 18: 2779–2788？？
[23]
12 Chen Z, Kadowaki S, Hagiwara Y, et al. Protection against influenza B virus infection by immunization with DNA vaccines. Vaccine, 2001,19: 1446–1455？？
[24]
13 Chen J, Fang F, Li X, et al. Protection against influenza virus infection in BALB/c mice immunized with a single dose ofneuraminidase-expressing DNAs by electroporation. Vaccine, 2005, 23: 4322–4328？？
[25]
14 Luxembourg A, Evans C F, Hannaman D, et al. Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther,2007, 7: 1647–1664？？
[26]
15 Luckay A, Sidhu M K, Kjeken R, et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specificimmune responses in rhesus macaques. J Virol, 2007, 81: 5257–5269？？
[27]
16 Nguyen H H, Michael Z, Ivanov I I, et al. Heterosubtypic immunity to influenza A virus infection requires a properly diversified antibodyrepertoire. J Virol, 2007, 81: 9331–9338？？
[28]
17 Zhang L, Nolan E, Kreitschitz S, et al. Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation. BiochimBiophys Acta, 2002, 1572: 1–9
[29]
18 Thomas R, Robert A A, Jean H P, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination ofserologic assays. J Clin Microbiol, 1999, 37: 937–943
[30]
19 Holman D H, Wang D, Raja N U, et al. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responsesagainst H5N1 avian influenza viruses. Vaccine, 2008, 26: 2627–2639？？
